Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

Study Identifier:
C08-002B
ClinicalTrials.gov Identifier:
NCT00844844
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Atypical Hemolytic Uremic Syndrome
Study Drug
  • Drug: Eculizumab
Date
May 2009 - Sep 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 17 Years
Requirements Information
Sex
Female & Male
Age
12 - 17 Years

Study Details

Medical Condition
  • Atypical Hemolytic Uremic Syndrome
Study Drug
  • Drug: Eculizumab
Date
May 2009 - Sep 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 17 Years years
Requirements Information

Protocol Summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).

Trial Locations

Location
Status
Location
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Fort Wayne, Indiana, United States, 46804
Status
N/A
Location
New York, New York, United States, 10032
Status
N/A
Location
New York, New York, United States, 10065
Status
N/A
Location
Grapevine, Texas, United States, 76051
Status
N/A
Location
Houston, Texas, United States, 77030
Status
N/A
Go to page